Morphine Sulphate Wockhardt Uk (Morphine Sulfate)

Morphine sulfate binds to mu‑opioid receptors in the brain and spinal cord, activating inhibitory pathways that reduce the release of neurotransmitters involved in pain signaling. This decreases neuronal excitability and blocks the transmission of nociceptive signals, resulting in analgesia and sedation.

The appropriate dose of morphine sulfate is determined by the prescribing clinician based on the patient’s pain severity, prior opioid exposure, renal and hepatic function, and route of administration. Dosage regimens are individualized and should follow local prescribing guidelines.

Morphine sulfate is classified as Pregnancy Category C, indicating that risk cannot be ruled out and it should be used only if the potential benefit justifies the potential fetal risk. It is excreted in breast milk; therefore, caution is advised when breastfeeding, and alternatives should be considered when possible.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and necessary import documentation.

Morphine sulfate is a prototypical mu‑opioid receptor agonist with a well‑characterized efficacy and safety profile. Compared with newer synthetic opioids, it has a longer history of clinical use, predictable pharmacokinetics, and is often less expensive, but it may have a higher incidence of certain side effects such as constipation and histamine release.

Morphine Sulfate injectable solution should be stored at controlled room temperature, below 25 °C, in its original packaging. Protect it from moisture, direct sunlight, and extreme temperature fluctuations. Do not freeze the product; discard any solution that appears discolored or contains particulate matter.

Morphine sulfate is supplied as a sterile injectable solution and can be given intramuscularly, intravenously, or subcutaneously. The route, rate of infusion, and dose are selected by the prescriber based on clinical need, with careful monitoring for efficacy and adverse effects during and after administration.

The most serious risks include respiratory depression, severe hypotension, and the potential for dependence or abuse. Patients should be monitored closely for signs of inadequate ventilation, sudden drops in blood pressure, and any behavioral changes indicating misuse.

Morphine sulfate is contraindicated in patients with known hypersensitivity to morphine or other opioids, those who have taken monoamine oxidase inhibitors within the past 14 days, and individuals with significant respiratory depression or uncontrolled asthma. Caution is also advised in patients with severe head injury or increased intracranial pressure.